Clincosm LogoSign in Get a demo

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Sponsor
University of Washington (Other)
Overall Status
Terminated
CT.gov ID
NCT01729884
Collaborator
National Cancer Institute (NCI) (NIH)
3
Enrollment
1
Location
1
Arm

Study Details

Study Description

Brief Summary

This phase II trial studies how well vaccine therapy works in treating patients with stage IV hormone receptor positive breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.

Condition or Disease Intervention/Treatment Phase
  • Biological: HER-2/neu peptide vaccine
 Phase 2

Detailed Description

PRIMARY OBJECTIVES:

  1. To quantify and characterize human epidermal growth factor receptor 2 (HER2)-specific central memory T cell (TCM) and effector memory T cell (TEM) subsets in peripheral blood mononuclear cell (PBMC) of patients vaccinated with a HER2 cytotoxic T lymphocyte (CTL) peptide-based vaccine.

  2. To evaluate the feasibility of expanding HER2-specific effector T cells (TE) derived from HER2-specific TCM or TEM precursors in patients vaccinated with a HER2 CTL peptide-based vaccine and characterize their function.

SECONDARY OBJECTIVES:
  1. To evaluate the safety of administering a HER2 CTL peptide-based vaccine in patients who are receiving trastuzumab and/or lapatinib (lapatinib ditosylate).
OUTLINE:

Patients receive HER-2/neu peptide vaccine intradermally (ID) once monthly for 3 months.

After completion of study treatment, patients are followed up at 4 weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
3 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer
Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Jun 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment (HER-2/neu peptide vaccine)

Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.

Biological: HER-2/neu peptide vaccine
Given ID
Other Names:
  • HER-2

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Quantification and characterization of HER2-specific TCM and TEM subsets in PBMC [Up to 4 weeks]

      Wilson score 90% confidence intervals will be reported.

    2. Evaluation of function and phenotype of HER2-specific TE cells derived from HER2-specific TCM and TEM subsets [Up to 4 weeks]

      Wilson score 90% confidence intervals will be reported. Determined by flow cytometry and reported using descriptive statistics and graphical summaries.

    Secondary Outcome Measures

    1. The number of subjects reporting adverse events, evaluated according to the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [Up to 4 weeks]

      All, severe or worse, serious and related events will be quantified.

    2. The percent of subjects recording adverse events, evaluated according to the CTEP CTCAE version 4.0 [Up to 4 weeks]

      All, severe or worse, serious and related events will be quantified.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients with HER2+ stage IV breast cancer that have been maximally treated and not in a complete remission

    • Patients must have measurable disease per imaging studies performed within 60 days of enrollment as described below:

    • Extra skeletal disease that can be measured with conventional or spiral computed tomography (CT) techniques

    • Skeletal or bone-only disease that is measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) or magnetic resonance imaging (MRI)

    • Patients can be receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy

    • HER2 overexpression in the primary tumor or metastasis by immunohistochemistry (IHC) of 3+, or documented gene amplification by fluorescent in situ hybridization (FISH) analysis

    • Patients must be human leukocyte antigen (HLA)-A2 positive

    • Eastern Cooperative Oncology Group (ECOG)/Zubrod scale of =< 1

    • Patients must be off immunosuppressive treatments (i.e., chemotherapy or systemic steroids) 3 weeks prior to first vaccine

    • Patients on trastuzumab must have a baseline left ventricular ejection fraction (LVEF) measured by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= the lower limit of normal for the facility within 3 months of enrollment to study

    • Subjects of reproductive ability must agree to use contraceptives during the entire study period

    Exclusion Criteria:

    • White blood cell (WBC) < 3000/mm^3

    • Hemoglobin (Hgb) < 10 mg/dl

    • Platelets < 100,000/mm^3

    • Serum creatinine > 2.0 mg/dl

    • Serum bilirubin > 1.5 x upper limit of normal

    • Any contraindication to receiving sargramostim (GM-CSF) based vaccine products

    • Concurrent enrollment in other treatment studies

    • New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina

    • Pregnant or breast-feeding women

    • History of disorders associated with immunosuppression such as human immunodeficiency virus (HIV)

    • Active brain metastasis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle Washington United States 98109

    Sponsors and Collaborators

    • University of Washington
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Lupe Salazar, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mary (Nora) Disis, Principal Investigator, University of Washington
    ClinicalTrials.gov Identifier:
    NCT01729884
    Other Study ID Numbers:
    • 7905
    • NCI-2012-02223
    • 7905
    • P30CA015704
    • P50CA138293
    First Posted:
    Nov 20, 2012
    Last Update Posted:
    Apr 11, 2017
    Last Verified:
    Apr 1, 2017
    Additional relevant MeSH terms:
    Breast Neoplasms
    Breast Neoplasms, Male

    Study Results

    No Results Posted as of Apr 11, 2017